Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.67 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945299 | 0.87 | L3MBTL1 (0.69) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL8300753 | 0.87 | L3MBTL1 (0.69) | L3MBTL1AKT1NPSR1HDAC3HDAC1 | |
| SCHEMBL6629239 | 0.85 | L3MBTL1 (0.73) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL12643699 | 0.84 | L3MBTL1 (0.64) | L3MBTL1AKT1HDAC3HDAC1HDAC2 | |
| SCHEMBL8899583 | 0.84 | L3MBTL1 (0.76) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL13823926 | 0.84 | L3MBTL1 (0.72) | L3MBTL1 | |
| SCHEMBL5713023 | 0.83 | L3MBTL1 (0.63) | L3MBTL1AKT1NPSR1HDAC3HDAC1 | |
| SCHEMBL9781776 | 0.83 | L3MBTL1 (0.78) | L3MBTL1 | |
| SCHEMBL9434959 | 0.83 | L3MBTL1 (0.78) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL9434778 | 0.83 | L3MBTL1 (0.78) | L3MBTL1HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020011254-A1 | FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-01-16 | — | — | WO | disclosed |